237 related articles for article (PubMed ID: 14510923)
1. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis.
Ramadan NM; Skljarevski V; Phebus LA; Johnson KW
Cephalalgia; 2003 Oct; 23(8):776-85. PubMed ID: 14510923
[TBL] [Abstract][Full Text] [Related]
2. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
3. Lasmiditan mechanism of action - review of a selective 5-HT
Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
[TBL] [Abstract][Full Text] [Related]
4. Targeted 5-HT
Vila-Pueyo M
Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
[TBL] [Abstract][Full Text] [Related]
5. Is selective 5-HT
Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
[TBL] [Abstract][Full Text] [Related]
6. Serotonin in migraine: theories, animal models and emerging therapies.
Johnson KW; Phebus LA; Cohen ML
Prog Drug Res; 1998; 51():219-44. PubMed ID: 9949863
[TBL] [Abstract][Full Text] [Related]
7. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
[TBL] [Abstract][Full Text] [Related]
8. Targeting the 5-HT
Huang PC; Yang FC; Chang CM; Yang CP
Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
[TBL] [Abstract][Full Text] [Related]
9. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.
Phebus LA; Johnson KW; Zgombick JM; Gilbert PJ; Van Belle K; Mancuso V; Nelson DL; Calligaro DO; Kiefer AD; Branchek TA; Flaugh ME
Life Sci; 1997; 61(21):2117-26. PubMed ID: 9395253
[TBL] [Abstract][Full Text] [Related]
10. Migraine: pathophysiology, pharmacology, treatment and future trends.
Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B; Israel H; Neeb L; Reuter U
Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
[TBL] [Abstract][Full Text] [Related]
12. Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation.
Wainscott DB; Johnson KW; Phebus LA; Schaus JM; Nelson DL
Eur J Pharmacol; 1998 Jul; 352(1):117-24. PubMed ID: 9718276
[TBL] [Abstract][Full Text] [Related]
13. 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?
Neeb L; Meents J; Reuter U
Neurotherapeutics; 2010 Apr; 7(2):176-82. PubMed ID: 20430316
[TBL] [Abstract][Full Text] [Related]
14. G-protein activation at 5-HT1A receptors by the 5-ht1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines.
Dupuis DS; Colpaert FC; Pauwels PJ
Br J Pharmacol; 1998 May; 124(2):283-90. PubMed ID: 9641544
[TBL] [Abstract][Full Text] [Related]
15. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein.
Cohen ML; Schenck K
J Pharmacol Exp Ther; 1999 Sep; 290(3):935-9. PubMed ID: 10454462
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT
Jin C; Yi C; Zhong W; Xue Y; Chen K; Deng K; Wang Z; Wang T
Eur J Med Chem; 2021 Dec; 225():113782. PubMed ID: 34419891
[TBL] [Abstract][Full Text] [Related]
17. Lasmiditan for the treatment of migraine.
Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
[TBL] [Abstract][Full Text] [Related]
18. Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog.
Adham N; Bard JA; Zgombick JM; Durkin MM; Kucharewicz S; Weinshank RL; Branchek TA
Neuropharmacology; 1997; 36(4-5):569-76. PubMed ID: 9225282
[TBL] [Abstract][Full Text] [Related]
19. 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks.
Olesen J
Cephalalgia; 2010 Oct; 30(10):1157-8. PubMed ID: 20855360
[No Abstract] [Full Text] [Related]
20. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.
Ferrari MD; Färkkilä M; Reuter U; Pilgrim A; Davis C; Krauss M; Diener HC;
Cephalalgia; 2010 Oct; 30(10):1170-8. PubMed ID: 20855362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
